Search Results

Ansys (NASDAQ: ANSS) today announced that it is adopting NVIDIA Omniverse application programming interfaces (APIs) to offer 3D-IC designers valuable insights from Ansys’ physics solver results through real-time visualization.

MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm is pleased to announce its role in the U.S. Food and Drug Administration’s (FDA) 510(k) clearance for 3D Systems’ 3D-printed, patient-specific cranial implant solution — VSP® PEEK Cranial Implant.

Laxxon Medical announced the development program for LXM.2, a 3D printed oral glucagon-like peptide-1 receptor agonist for the treatment of adults and pediatric patients 12 years and older with obesity.

Align Technology, Inc. announced that it has completed the acquisition of privately-held Cubicure GmbH, a pioneer in direct 3D printing solutions for polymer additive manufacturing that develops, produces, and distributes innovative materials, equipment, and processes for novel 3D printing solutions.

Stratasys Ltd. and Ricoh USA, Inc. announced the enrollment of the first patient in a groundbreaking clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology.

Ricoh USA, Inc. and Stratasys Ltd. (NASDAQ: SSYS) today announced the enrollment of the first patient in a groundbreaking clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology.

ZSFab Inc., a leading expert in digitally structured materials and 3D printed orthopedic devices, proudly announces the first clinical utilization of its recently launched InterConnect™ 3D Printed Ti Lumbar Interbody System.

Predictive Oncology Inc. today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development.

PolyPid Ltd. announced that it will host a virtual Key Opinion Leader event on Monday, June 17, 2024, at 10:00 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company’s ongoing D-PLEX100 Phase 3 trial.